Acute organizing interstitial pneumonia and interstitial nephritis due to salazosulfapyridine in a patient with rheumatoid arthritis

Allergology International

Volumn 52, Issue 1, 2003, Pages 37-41

  Ogawa, Haruhiko ^a   Fujimura, Masaki ^b   Nakashima, Akikatsu ^a   Tofuku, Yohei ^a   Ojima, Tomohiro ^a   Kitagawa, Masanobu ^c  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c Department of Surgery Hokuriku Central Hospital   (Japan)

Author keywords

Azulfidine EN; Drug induced pneumonitis; Interstitial nephritis; Rheumatoid arthritis; Salazosulfapyridine

Indexed keywords

AZULFIDINE EN; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COUGHING; DYSPNEA; FEVER; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERSTITIAL NEPHRITIS; INTERSTITIAL PNEUMONIA; JAPAN; KIDNEY DYSFUNCTION; LUNG BIOPSY; LUNG INFILTRATE; LYMPHOCYTE TRANSFORMATION TEST; MALE; ORGANIZING PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STOMACH; SYMPTOM;

EID: 0037344413     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1592.2003.00276.x     Document Type: Article

References (16)

1. Boyd BO, Gibbs AR, Smith AP. Fibrosing alveolitis due to sulphasalazine in a patient with rheumatoid arthritis. Br. J. Rheumatol. 1990; 29: 222-4.
2. Pinals RS, Kaplan SB, Lawson JG, Hepburn B. Sulfasalazine in rheumatoid arthritis. Arthritis Rheum. 1986; 29: 1427-34.
3. Stephen MS, Eric JO, Bernard JR, Cristopher AM, Erik DC, Thomas AD. Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis. Chest 1996; 110: 556-9.
4. Leino R, Liippo K, Ekfors T. Sulphasalazine-induced reversible hypersensitivity pneumonitis and fatal fibrosing alveolitis: Report of two cases. J. Int. Med. 1991; 229: 553-6.
5. Steinbroker O, Traeger CH, Batteman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659-62.
6. American Thoracic Society. Standardization of spriomtery: 1987 update. Am. Rev. Respir. Dis. 1987; 136: 1285-98.
7. Rosenow EC. The spectrum of drug-induced pulmonary diseases. Ann. Intern. Med. 1972; 77: 977-91.
8. Ogawa H, Fujimura M, Matsuda T et al. Pulmonary infiltrates with eosinophils due to naproxan. Jpn. J. Med. 1991; 30: 32-4.
9. Ogawa H, Fujimura M, Heki U, Kitagawa M, Matsuda T. Eosinophilic bronchitis presenting with only severe dry cough due to bucillamine. Respir. Med. 1995; 89: 219-21.
10. Williams T, Eidus L, Thomas P. Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy. Chest 1982; 81: 766-8.
11. Liebow AA, Carrington CB. The eosinophilic pneumonias. Medicine 1969; 48: 251-85.
12. Ogawa H, Fujimura M, Amaike S, Matsumoto Y, Kitagawa M, Matsuda M. Eosinophilic pneumonia caused by Alternaria alternata. Allergy 1997; 52: 1005-8.
13. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001; 56: 622-7.
14. Rajasekaran BA, Shovlin D, Lord P, Kelly CA. Interstitial lung disease in patients with rheumatoid arthritis: A comparison with cryptogenic fibrosing alveolitis. Rheumatology 2001; 40: 1022-5.
15. Ransford RA, Langman MJ. Sulphasalazine and mesalazine. Serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-9.
16. Frandsen NE, Saugmann S, Marcussen N. Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron 2002; 92: 200-2.